Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c2849ede0fc4d116b2c0dcf64419d2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74bfcee2cede2f3244573443b890393a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_299fee22c3320b7a8ae5ebb6a85038a0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2be18742ec40b7f3ba606daef7bc3777 |
publicationDate |
2016-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9382316-B2 |
titleOfInvention |
Humanized anti-EMAP II antibody and use thereof |
abstract |
The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10132815-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11104728-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015377908-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021388076-A1 |
priorityDate |
2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |